A combined analysis of cancer patient information from multiple open databases found that NOTCH mutations increased the efficacy of PD-1 inhibitors by 2.2-fold and reduced the risk of disease progression by 39%; patients had a 44% lower risk of death (98). The gene discussed is PDCD1; the disease is cancer.